Leflunomide Aspire Pharma (Leflunomide)

Leflunomide works by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. This inhibition limits the availability of nucleotides required for the proliferation of activated T‑lymphocytes, thereby suppressing the autoimmune inflammatory response that drives joint damage.

The dosing regimen for Leflunomide Aspire Pharma is individualized and set by the prescribing healthcare professional based on the patient’s clinical condition, disease severity, and laboratory parameters. Physicians determine the appropriate starting dose and any subsequent adjustments during treatment.

Leflunomide is classified as pregnancy category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. It should not be used by women who are pregnant, planning to become pregnant, or breastfeeding. Effective contraception is required for women of child‑bearing potential during treatment and for a defined period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Leflunomide Aspire Pharma. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled logistics) and the necessary import documentation.

The most common alternative DMARD for rheumatoid and psoriatic arthritis is methotrexate. While both agents suppress immune activity, methotrexate primarily inhibits dihydrofolate reductase, whereas Leflunomide blocks pyrimidine synthesis. Leflunomide may be preferred in patients who cannot tolerate methotrexate’s hepatic or gastrointestinal side effects, but it carries its own risks such as hepatotoxicity and hypertension.

Leflunomide Aspire Pharma tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

The medication is supplied as oral tablets that are taken whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and should not crush, split, or chew the tablets unless specifically instructed to do so.

Serious adverse events include hepatotoxicity (significant liver enzyme elevations or liver injury), severe infections due to immunosuppression, and rare hematologic disorders such as aplastic anemia or pancytopenia. Regular monitoring of liver function tests, complete blood counts, and blood pressure is essential to detect these risks early.

Leflunomide is contraindicated in pregnant women, individuals with severe hepatic impairment, patients with uncontrolled hypertension, and those with known hypersensitivity to Leflunomide or any of its excipients. Caution is also advised for patients with active infections, immunodeficiency, or those receiving live vaccines.